(Total Views: 492)
Posted On: 07/04/2025 8:49:15 AM
Post# of 156178

INmune Bio's TNF inhibitor targeting neuroinflammation recently missed their Alzheimer's phase 2 primary endpoint. Nevertheless, they intend to apply for BTD.
https://www.inmunebio.com/index.php/newsroom/...0630043503
https://www.inmunebio.com/index.php/newsroom/...0630043503

